Gareth Wakefield

DeepMatter Group Plc is engaged in the development of a number of projects targeting new chemicals, materials, formulations, and pharmaceuticals in commercial areas. It operates through the following segments: DeepMatter and InfoChem. The DeepMatter segment owns, develops and is in the early stage of exploiting intellectual property, software, hardware and data analysis capabilities combined as a visionary, disruptive platform called DigitalGlassware, enabling step changes in productivity and discovery for scientists in the pharma and life science sectors. The InfoChem segment develops and commercialises cheminformatics software to handle, store and retrieve chemical structures and reactions for application in pharma, life sciences, and scientific publications. The company was founded by Jon-Paul Griffiths and Mark G. Moloney on June 13, 2006 and is headquartered in Glasgow, the United Kingdom.

Xerion Healthcare Ltd. develops and commercializes nanoparticle treatment to cure head, and neck and lung cancer. It injects Nanoparticles into tumours and generates free radicals by splitting water rather than interacting with oxygen. The firm’s nanoparticles are based on titanium dioxide, a common, non-toxic, semiconductor material. The company was founded by Gareth Wakefield and Helen Townley in 2015 and is headquartered in Thame, the United Kingdom.